Humanized Mouse and Rat Model Market | Growing Demand for Personalized Medicine

PUNE, India, 2020-May-28 — /EPR Network/ —

The report “Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) – Global Forecast“

[189 Pages Report] MarketsandMarkets forecast the Humanized Mouse Model Market to grow USD 128.9 million, at a compounded annual growth rate (CAGR) of 9.9% during the forecast period.

The Humanized Rat Model Market is expected to reach USD 8.9 million, at a CAGR of 8.4% during the forecast period.

Market Dynamics:

Driver: Growing demand for personalized medicine;

Personalized medicine is the process of developing tailored medicines to target individualized treatment and care based on personal and genetic variations. These medicines are designed through the use of animal models, particularly mice models. Immune-deficient models are transplanted with human tissues and the disease expressed is recorded. This is followed by treating the model with a whole series of drugs or gene therapies to find the most suitable treatment, thus generating suitable or personalized medicine for patients.

Currently, cancer is a major burden on the healthcare systems across geographies. By 2020, the direct/indirect cost of cancer is estimated to be USD 300 billion in the US. Several in vitro and in vivo strategies are being developed in an attempt to combat the rising prevalence of cancer and offer effective treatments to patients.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955

By type, the humanized mouse model segment to account for the largest share of the humanized mouse and rat model market in 2017

Based on type, the market is segmented into humanized mouse and humanized rat. The Humanized mouse market is further segmented into cell-based and genetic based humanized mouse model. The genetic humanized mouse models segment accounted for the largest share of the market. The large share of this segment can be attributed to the wide use of genetic humanized mouse models in the analysis of compounds, biological efficacy and safety testing, study of drug metabolism and disposition, and investigation of immune system development and function.

By Application, the oncology segment to account for the largest share of the humanized mouse model market in 2017

Based on application, the market is segmented into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The oncology segment is expected to witness the highest growth, owing to the rising number of cancer research activities and increasing innovation to develop humanized mouse models tailored to meet the specific needs of cancer research.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955

The North American region is leading the humanized mouse models’ market is expected to account for the largest share of the market in 2017. Growth in this regional segment can primarily be attributed to growing biomedical research, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, increasing monoclonal antibody production in the US along with growing stem cell research, and government support for the development of protein drugs in Canada.

Key Market Players

The major market players in the humanized mouse models market include The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US).

The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).